EndoResFellow said:Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts.
This is exactly what I could not find anywhere else. Taking it to my next appointment.
Clinical perspective, offered as context rather than as advice. The distinction that resolves most of these threads is between what is true on average and what is true for one person. Both are real; they answer different questions and get quoted as if they were the same one.
Dr.NutriCornell said:The GIP arm is doing real work rather than padding the label.
This is where I part company with the consensus forming above. The "tirzepatide is simply better" summary irritates me. It is better on mean weight loss, and the cardiovascular outcome evidence is far thinner than semaglutide's. If the reason for treating is cardiovascular risk rather than weight, the evidence base points the other way.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsAdding the numbers, since they settle part of this. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.
Worth separating that from tirzepatide, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.